Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2013 | Pages:
88 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global Human Papillomavirus (HPV) testing and Pap test market are expected to reach USD 5.6 billion by 2024, according to a new report by Grand View Research Inc.The market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer. For instance, the CDC advocates cervical cancer screening tests for women above the age of 30 as it was found that the cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in 100,000). In addition to carrying out awareness campaigns, the government and key industrial players are providing funding to universities for the development of enhanced technologies to facilitate effective screening, which would mitigate the incidence of late-stage cervical cancer. In this direction,in April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test (Roche Molecular Systems), as a primary screening test. A study conducted by the scientists of Hologic, Inc. and University of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV and Pap) stating that the Paptest identifies cellular abnormalities and the HPV test detects suspicious viruses, hence improving the efficiency and providing the best results that are cost-effective and convenient to the patients. Further key findings from the report suggest: The cervical cancer screening segment dominated the market in 2015 owing to the introduction of advanced technologies for the screening and detection of cervical cancer. For instance, in May 2016,Hologic Inc. determined that HPV and Pap co-testing was the most effective in the screening of cervical cancer. The laboratories segment dominated the HAV and Pap test market in 2015 owing to the increased performance in the diagnosis of cervical cancer cases. As per the CDC statistics, approximately 21.7 million tests were performed in the U.S.; hence,the hospitalssegmentis expected to witnessa rapid growthin the coming years due to the increasing number of diagnostic tests performed in-house and also the availability of advanced technologies. In 2015, North America held the largest share in terms of revenue owing to the continual introduction ofinnovated technologies to improve patient care and diagnosis. In addition, the high number of positive cases being detected,along with the rising death toll (i.e., 2.6 in 1,00,000), has compelled the government to conduct awareness programmes about the early diagnosis and treatment of cervical cancer, which is a key factor for the large market share. In April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence of cancer-causing high-risk HPVs. It provides information regardingpatients' risk of developing cervical cancer. The Cobas HPV test is used to specifically identify HPV 16 and HPV 18as well as12 other high-risk HPVs from the cervical cell sample in women older than 25 years of age. AsiaPacific is expected to grow at a high CAGR in the coming years. As per the cancer council, 61% of the Australian women are screened for cervical cancer every two years, out of which around 26% who have been detected throughthe normal Pap test undergo an early re-screening more often than the recommended two years of interval. Some key players in the market are QiagenN. V., Hologic, Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson and Company.These market players are in the process of introducing tests to change the traditional methods of individual HPV and Pap tests and introducenewer techniques or devices to improve the efficiency and convenience. For instance, in February 2016, Quest acquiredClinical Laboratory Partner's outreach laboratory service business. This acquisition is expected to provide the patients a broader service network with better quality, affordability, and convenience.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Research methodology
1.2. Research scope &assumption
1.3. List of data sources
Chapter 2. Executive Summary
2.1. HPV testing and Pap test-Industry snapshot and key buying criteria, 2016 - 2024
Chapter 3. HPV Testing and Pap Test Industry Outlook
3.1. HPV testing and Pap test market segmentation
3.2. HPV testing and Pap test market size and growth prospects, 2016 - 2024
3.3. HPV testing and Pap test: Market dynamics
3.3.1. Market driver analysis
3.3.1.1. Introduction of advanced technological innovations and Industrial consolidation
3.3.1.2. Increased government initiatives.
3.3.2. Market restraint analysis
3.3.2.1. Legal issues (Regulatory guideline changes for cervical cancer)
3.3.2.2. Vaccination against HPV
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. HPV testing and Pap test competitive landscape
3.6.1. Company market share analysis, 2015
3.6.2. Competitive landscape: Market position analysis (based on products, regional presence, and strategic initiatives)
3.7. HPV testing and Pap test market PESTEL analysis, 2015
Chapter 4. HPV Testing and Pap TestApplication Outlook
4.1. HPV testing and Pap test market share by application, 2016 & 2024
4.2. Cervical cancer screening test
4.2.1. Cervical cancer screening test market estimates, 2013 - 2015 (USD Million)
4.2.2. Cervical cancer screening test forecasts, 2016 - 2024 (USD Million)
4.3. Vaginal cancer screening test
4.3.1. Vaginal cancer screening test market estimates, 2013 - 2015 (USD Million)
Vaginal cancer screening test forecasts, 2016 - 2024 (USD Million)
4.4. Other
4.4.1. Other market estimates, 2013 - 2015 (USD Million)
4.4.2. Other market forecasts, 2016 - 2024 (USD Million)
Chapter 5. HPV Testing and Pap TestEnd-Use Outlook
5.1. HPV testing and Pap test market share by end-use, 2016 & 2024
5.2. Hospitals
5.2.1. Hospitals market estimates, 2013 - 2015 (USD Million)
5.2.2. Hospitals market forecasts, 2016 - 2024 (USD Million)
5.3. Laboratories
5.3.1. Laboratories market estimates, 2013 - 2015 (USD Million)
5.3.2. Laboratories market forecasts, 2016 - 2024 (USD Million)
5.4. Clinical research institutes
5.4.1. Clinical research institutes market estimates 2013 - 2015 (USD Million)
5.4.2. Clinical research forecasts, 2016 - 2024 (USD Million)
Chapter 6. HPV Testing and Pap Test Regional Outlook
6.1. North America
6.1.1. HPV testing and Pap test market estimates, by application, 2013 - 2015 (USD Million)
6.1.2. HPV testing and Pap test market forecasts, by application, 2016 - 2024 (USD Million)
6.1.3. HPV testing and Pap test market estimates, by end-use, 2013- 2015 (USD Million)
6.1.4. HPV testing and Pap test market forecast, by end-use, 2016 - 2024 (USD Million)
6.1.4.1. U.S.
6.1.4.1.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.1.4.1.2. HPV testing and Pap test market forecasts, 2016 - 2024 (USD Million)
6.1.4.2. Canada
6.1.4.2.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.1.4.2.2. HPV testing and Pap test market forecasts, 2016 - 2024 (USD Million)
6.2. Europe
6.2.1. HPV testing and Pap test market estimates, by application, 2013 - 2015 (USD Million)
6.2.2. HPV testing and Pap test market forecasts, by application, 2016 - 2024 (USD Million)
6.2.3. HPV testing and Pap test market estimates, by end-use, 2013 - 2015 (USD Million)
6.2.4. HPV testing and Pap test forecast, by end-use, 2016 - 2024 (USD Million)
6.2.4.1. UK
6.2.4.1.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.2.4.1.2. HPV testing and Pap testmarket forecasts, 2016 - 2024 (USD Million)
6.2.4.2. Germany,
6.2.4.2.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.2.4.2.2. HPV testing and Pap testmarket forecasts, 2016 - 2024 (USD Million)
6.3. Asia Pacific
6.3.1. HPV testing and Pap test market estimates, by application, 2013 -2015 (USD Million)
6.3.2. HPV testing and Pap testmarket forecasts, by application, 2016-2024 (USD Million)
6.3.3. HPV testing and Pap test market estimates, by end-use, 2013 -2016 (USD Million)
6.3.4. HPV testing and Pap test market forecasts, by end-use, 2016-2024 (USD Million)
6.3.4.1. India
6.3.4.1.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.3.4.1.2. HPV testing and Pap testmarket forecasts, 2016 - 2024 (USD Million)
6.3.4.2. China
6.3.4.2.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.3.4.2.2. HPV testing and Pap testmarket forecasts, 2016 - 2024 (USD Million)
6.3.4.3. Japan
6.3.4.3.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.3.4.3.2. HPV testing and Pap testmarket forecasts, 2016 - 2024 (USD Million)
6.4. Latin America
6.4.1. HPV testing and Pap test market estimates, by application, 2013 -2015 (USD Million)
6.4.2. HPV testing and Pap testmarket forecasts, by application, 2016-2024 (USD Million)
6.4.3. HPV testing and Pap test market estimates, by end-use, 2013 -2016 (USD Million)
6.4.4. HPV testing and Pap testmarket forecasts, by end-use, 2016-2024 (USD Million)
6.4.4.1. Brazil
6.4.4.1.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.4.4.1.2. HPV testing and Pap testmarket forecasts, 2016 - 2024 (USD Million)
6.5. MEA
6.5.1. HPV testing and Pap test market estimates, by application, 2013 -2015 (USD Million)
6.5.2. HPV testing and Pap testmarket forecasts, by application, 2016-2024 (USD Million)
6.5.3. HPV testing and Pap test market estimates, by end-use, 2013 -2016 (USD Million)
6.5.4. HPV testing and Pap testmarket forecasts, by end-use, 2016-2024 (USD Million)
6.5.4.1. South Africa
6.5.4.1.1. HPV testing and Pap test market estimates, 2013 - 2015 (USD Million)
6.5.4.1.2. HPV testing and Pap test market forecasts, 2016 - 2024 (USD Million)
Chapter 7. Competitive Landscape
7.1. Abbott Laboratories
7.1.1. Company Overview
7.1.2. Financial Performance
7.1.3. Product Benchmarking
7.1.4. Strategic Initiatives
7.2. Qiagen N.V.
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Product Benchmarking
7.2.4. Strategic Initiatives
7.3. Quest diagnostics
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Product Benchmarking
7.3.4. Strategic Initiatives
7.4. Roche Diagnostics
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Product Benchmarking
7.4.4. Strategic Initiatives
7.5. Hologic Inc.
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Product Benchmarking
7.5.4. Strategic Initiatives
7.6. Becton Dickinsion and company
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Product Benchmarking
7.6.4. Strategic Initiatives
7.7. Arbor Vita corporation
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. Product Benchmarking
7.7.4. Strategic Initiatives
7.8. Femasys Inc.
7.8.1. Company Overview
7.8.2. Financial Performance
7.8.3. Product Benchmarking
7.8.4. Strategic Initiatives
7.9. OncoHealth corporation
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. Product Benchmarking
7.9.4. Strategic Initiatives
7.10. Seegene Inc.
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Product Benchmarking
7.10.4. Strategic Initiatives
List of Tables TABLE 1 HPV testing and Pap test Market - Industry Snapshot &Key Buying Criteria, 2013 - 2024 TABLE 2 Global HPV testing and Pap test market, by application, 2013 - 2024 (USD Million) TABLE 3 Global HPV testing and Pap test market, by end-use, 2013 - 2024 (USD Million) TABLE 4 Global HPV testing and Pap test market, by region, 2013 - 2024 (USD Million) TABLE 5 HPV testing and Pap test - Key market drivers analysis TABLE 6 HPV testing and Pap test - Key market restraints analysis TABLE 7 North America HPV testing and Pap testmarket, by application 2013 - 2024 (USD Million) TABLE 8 U.S. HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 9 U.S. HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 10 Canada HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 11 Canada HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 12 Europe HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 13 Europe HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 14 UK HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 15 UK HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 16 Germany HPV testing and Pap test market, by application, 2013 - 2024 (USD Million) TABLE 17 Germany HPV testing and Pap test market, by end-use, 2013 - 2024 (USD Million) TABLE 18 AsiaPacific HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 19 AsiaPacific HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 20 Japan HPV testing and Pap test market, by application, 2013 - 2024 (USD Million) TABLE 21 Japan HPV testing and Pap test market, by end-use, 2013 - 2024 (USD Million) TABLE 22 China HPV testing and Pap test market, by application, 2013 - 2024 (USD Million) TABLE 23 China HPV testing and Pap test market, by end-use, 2013 - 2024 (USD Million) TABLE 24 India HPV testing and Pap test market, by application, 2013 - 2024 (USD Million) TABLE 25 India HPV testing and Pap test market, by end-use, 2013 - 2024 (USD Million) TABLE 26 Latin America HPV testing and Pap test market, by application, 2013 - 2024 (USD Million) TABLE 27 Latin America HPV testing and Pap test market, by end-use, 2013 - 2024 (USD Million) TABLE 28 Brazil HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 29 Brazil HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 30 MEA HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 31 MEA HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million) TABLE 32 South Africa HPV testing and Pap testmarket, by application, 2013 - 2024 (USD Million) TABLE 33 South Africa HPV testing and Pap testmarket, by end-use, 2013 - 2024 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
